Ascendis Pharma A/S
ASND
Rank in Stocks
#1499
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Share Price
$234.36
Market Cap
$14.62B
Change (1 day)
1.92%
Change (1 year)
14.20%
Country
DK
Trade Ascendis Pharma A/S (ASND)
Category
Healthcare
Revenue for Ascendis Pharma A/S (ASND)
Revenue in Jun 2026 TTM: $1.25B
According to Ascendis Pharma A/S latest financial reports the company's current revenue (TTM) is $1.25B. In 2024 the company made a revenue of $378.39M an increase over the revenue in the year 2023 that was $294.85M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ascendis Pharma A/S from 2012 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.25B | 54.10% |
| 2025 | $811.56M | 114.48% |
| 2024 | $378.39M | 28.34% |
| 2023 | $294.85M | 437.13% |
| 2022 | $54.89M | 520.63% |
| 2021 | $8.84M | 4.45% |
| 2020 | $8.47M | -43.57% |
| 2019 | $15.01M | 23.42% |
| 2018 | $12.16M | 562.32% |
| 2017 | $1.84M | -62.12% |
| 2016 | $4.85M | -45.02% |
| 2015 | $8.81M | -47.90% |
| 2014 | $16.92M | -39.71% |
| 2013 | $28.06M | 36.53% |
| 2012 | $20.56M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 909.42% |
US
|
|
| $2.23B | 78.15% |
US
|
|
| $15.74B | 1,158.89% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 381.45% |
NL
|
